CovaLys

CovaLys is an innovative orally active Lysine covalent pan-IAP inhibitor of oncogenic Inhibitor of Apoptosis Proteins (IAPs)

CovaLys can be developed as a single-agent therapeutic or as a chemosensitizer in tumors that develop resistance to chemotherapy, radiation, or immunotherapy. 

Stage: late pre-clinical. First in class rationally designed Lys-covalent agent